Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PBYI's Cash to Debt is ranked higher than
84% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. PBYI: No Debt )
PBYI' s 10-Year Cash to Debt Range
Min: N/A   Max: No Debt
Current: No Debt


Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6421
N/A
No Debt
Interest Coverage No Debt
PBYI's Interest Coverage is ranked higher than
82% of the 680 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PBYI: No Debt )
PBYI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 131.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -94.00
PBYI's ROE (%) is ranked higher than
57% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. PBYI: -94.00 )
PBYI' s 10-Year ROE (%) Range
Min: -141.23   Max: -37.64
Current: -94

-141.23
-37.64
ROA (%) -80.62
PBYI's ROA (%) is ranked higher than
55% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. PBYI: -80.62 )
PBYI' s 10-Year ROA (%) Range
Min: -1700   Max: -36.94
Current: -80.62

-1700
-36.94
ROC (Joel Greenblatt) (%) -8590.39
PBYI's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. PBYI: -8590.39 )
PBYI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7408.23   Max: -2978.59
Current: -8590.39

-7408.23
-2978.59
EBITDA Growth (3Y)(%) 53.30
PBYI's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. PBYI: 53.30 )
PBYI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 598.6
Current: 53.3

0
598.6
EPS Growth (3Y)(%) 53.00
PBYI's EPS Growth (3Y)(%) is ranked higher than
96% of the 824 Companies
in the Global Biotechnology industry.

( Industry Median: -4.80 vs. PBYI: 53.00 )
PBYI' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 883
Current: 53

0
883
» PBYI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PBYI Guru Trades in Q2 2014

Steven Cohen 327,900 sh (unchged)
Pioneer Investments Sold Out
Jim Simons Sold Out
» More
Q3 2014

PBYI Guru Trades in Q3 2014

RS Investment Management 92,188 sh (New)
Jim Simons 30,200 sh (New)
Steven Cohen Sold Out
» More
Q4 2014

PBYI Guru Trades in Q4 2014

RS Investment Management Sold Out
Jim Simons Sold Out
» More
Q1 2015

PBYI Guru Trades in Q1 2015

Steven Cohen 9,100 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with PBYI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 20.10
PBYI's P/B is ranked lower than
52% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. PBYI: 20.10 )
PBYI' s 10-Year P/B Range
Min: 0   Max: 62.4
Current: 20.1

0
62.4
EV-to-EBIT -33.29
PBYI's EV-to-EBIT is ranked higher than
58% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PBYI: -33.29 )
PBYI' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -33.29

Current Ratio 12.14
PBYI's Current Ratio is ranked higher than
90% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. PBYI: 12.14 )
PBYI' s 10-Year Current Ratio Range
Min: 0.67   Max: 91.42
Current: 12.14

0.67
91.42
Quick Ratio 12.14
PBYI's Quick Ratio is ranked higher than
90% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. PBYI: 12.14 )
PBYI' s 10-Year Quick Ratio Range
Min: 0.67   Max: 91.42
Current: 12.14

0.67
91.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 21.70
PBYI's Price/Net Cash is ranked higher than
68% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 440.10 vs. PBYI: 21.70 )
PBYI' s 10-Year Price/Net Cash Range
Min: 4.69   Max: 59.71
Current: 21.7

4.69
59.71
Price/Net Current Asset Value 21.70
PBYI's Price/Net Current Asset Value is ranked higher than
66% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 48.94 vs. PBYI: 21.70 )
PBYI' s 10-Year Price/Net Current Asset Value Range
Min: 4.26   Max: 55.48
Current: 21.7

4.26
55.48
Price/Tangible Book 20.10
PBYI's Price/Tangible Book is ranked lower than
52% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. PBYI: 20.10 )
PBYI' s 10-Year Price/Tangible Book Range
Min: 4.18   Max: 50.76
Current: 20.1

4.18
50.76
Earnings Yield (Greenblatt) -3.00
PBYI's Earnings Yield (Greenblatt) is ranked higher than
75% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. PBYI: -3.00 )
PBYI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.8   Max: 0
Current: -3

-3.8
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PB.Germany,
Puma Biotechnology Inc was incorporated in Delaware on April 27, 2007. The Company is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care It is engaged in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company currently licenses the rights to three drug candidates: PB272 (neratinib (oral)), which are being developed for the treatment of breast cancer patients, non-small cell lung cancer and patients with HER2 mutation-positive solid tumors; PB272 (neratinib (intravenous)), which are being developed for the treatment of cancer patients; and PB357, which it believes can serve as a backup compound to PB272, and which are being evaluated for further development. The Company focused on developing neratinib for the treatment of patients with human epidermal growth factor receptor type 2, or HER2-positive, breast cancer, HER2 mutated non-small cell lung cancer, HER2-negative breast cancer that has a HER2 mutation and other solid tumors that have an activating mutation in HER2. Therapeutic strategies, such as the use of Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1), produced by Genentech, and Tykerb (lapatinib), produced by GlaxoSmithKline, given either alone or in combination with chemotherapy, have been developed to improve the treatment of this cancer by binding to the HER2 protein. The Company licenses the exclusive rights to its current drug candidates from Pfizer Inc., or Pfizer, which had previously been responsible for the clinical trials regarding neratinib. The Company's competitors include Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK